Latest Funding News

Miramar Resources has granted Future Battery Minerals an exclusive option to acquire its Randalls Project for up to A$800,000, enabling a strategic refocus on its core gold and critical minerals assets.

BPM Minerals has secured the Forelands Gold Project with promising high-grade intercepts and divested its Claw Gold Project to Capricorn Metals, bolstering its cash position ahead of upcoming drilling.

Earth’s Energy Limited has halted further exploration spending on its South Australian and Queensland geothermal assets following an independent review, shifting focus to new project opportunities. The company maintains a healthy cash position while managing its existing licences conservatively.

Sarama Resources has completed the third tranche of its A$2.7 million equity placement, raising A$100,000 to advance exploration at its Cosmo Gold Project and support ongoing arbitration efforts.

Lynch Group Holdings Limited proposes a scheme of arrangement for acquisition by Hasfarm Bidco at a 23% premium, with unanimous board support and an independent expert endorsement. Shareholders will vote in November on a deal that would delist Lynch from the ASX.

Lynch Group Holdings Limited is moving closer to a $269 million acquisition by Hasfarm Bidco, with a shareholder meeting scheduled for 21 November 2025 to vote on the proposed scheme of arrangement. The transaction offers Lynch shareholders a 23% premium and is backed by an independent expert report and unanimous board recommendation.

Sultan Resources has increased its capital raising to $1.1 million through additional investor interest, with key approvals pending at the upcoming AGM. The funds aim to accelerate exploration at its promising projects in Namibia and Western Australia.

Sunrise Energy Metals secures renewed interest from the US Export-Import Bank for substantial debt financing, reinforcing the strategic importance of its Syerston Scandium Project amid a landmark US-Australia minerals pact.

Region Group delivered solid financial results for FY25 with modest growth in funds from operations and assets under management, while announcing a planned CEO retirement and maintaining positive guidance for FY26.

EMVision Medical Devices has closed its $2 million Share Purchase Plan ahead of schedule due to strong investor demand, signaling robust market interest in its neurodiagnostic technology.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Austral Resources Australia has locked in $40 million through a discounted share placement, setting the stage for its ASX reinstatement and ambitious expansion in Queensland's copper belt.